Global Genomic Cancer Testing Supply, Demand and Key Producers, 2026-2032
The global Genomic Cancer Testing market size is expected to reach $ 31364 million by 2032, rising at a market growth of 8.9% CAGR during the forecast period (2026-2032).
Genomic Cancer Testing refers to a class of molecular diagnostic technologies and services that analyze DNA, RNA and other molecular-level genetic information in a patient's tumor tissue or body fluids (such as circulating tumor DNA, ctDNA in blood) to identify gene mutations, copy number variations, gene fusions, abnormal expression or epigenetic changes related to the occurrence, development, subtype, treatment response and recurrence of cancer.
Gross Profit Margin Levels
Genomic cancer testing is an industry with high technological barriers, high data interpretation value, but also highly dependent on laboratory automation, sample size, and payment coverage. Overall, the industry's gross profit margin is typically significantly higher than that of routine testing projects. Based on comparable listed companies and industry experience, the gross profit margin for tumor gene testing business at comprehensive laboratory companies is commonly in the 50%-60% range, while leading pure molecular diagnostics/liquid biopsy/high-end CGP companies can typically reach 60%-75%. Among these, product lines with high automation, strong data reuse capabilities, high report added value, and good medical/commercial insurance coverage usually have even higher gross profit margins. Conversely, if a company primarily focuses on customized projects, low-throughput orders, complex manual interpretation, or regional sample delivery services, the gross profit margin will be diluted by channel costs, labor costs, and logistics costs. Therefore, the core of this industry is not 'how much money is made per sample tested,' but rather the quality of profitability is determined by platform-based testing capabilities, database capabilities, clinical evidence capabilities, and payment capabilities. The average gross profit margin level in this industry can generally be understood as higher than traditional pathology testing, lower than pure software SaaS, but significantly higher than most routine outsourced testing projects.
Industry Drivers
The growth of the genomic cancer testing industry is primarily driven by the continued rise in the cancer burden. WHO/IARC data shows that nearly 20 million new cancer cases were diagnosed globally in 2022, and this number is projected to reach 35 million by 2050. This directly increases the long-term demand for early screening, subtyping, targeted therapy selection, efficacy evaluation, and recurrence monitoring. Secondly, the increasing penetration rate of precision medicine is the most crucial catalyst for the industry. The NCI has explicitly incorporated biomarker testing into its treatment decision-making process, and the increasing number of FDA-approved companion diagnostics means that more and more anti-tumor drugs will rely on molecular testing for patient screening. Thirdly, improvements in the payment and regulatory environment are transforming tumor gene testing from an 'optional item' into 'part of the standard process'?the extension of CMS's NGS coverage policy and the clear payment pricing for high-value CGP projects are strengthening the industry's business loop. Meanwhile, liquid biopsy, methylation detection, MRD, AI interpretation, and multi-omics joint analysis are continuously improving detection sensitivity, lowering sampling thresholds, and extending testing scenarios from single-diagnosis to full-course disease management. Finally, pharmaceutical companies' demand for companion diagnostics, biomarker discovery, patient stratification, and real-world evidence is also driving the industry to upgrade from a single testing business to a composite market encompassing clinical services, drug development, and data asset operation.
This report studies the global Genomic Cancer Testing demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Genomic Cancer Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Genomic Cancer Testing that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Genomic Cancer Testing total market, 2021-2032, (USD Million)
Global Genomic Cancer Testing total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Genomic Cancer Testing total market, key domestic companies, and share, (USD Million)
Global Genomic Cancer Testing revenue by player, revenue and market share 2021-2026, (USD Million)
Global Genomic Cancer Testing total market by Type, CAGR, 2021-2032, (USD Million)
Global Genomic Cancer Testing total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Genomic Cancer Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Guardant Health (USA), Foundation Medicine (USA), Caris Life Sciences (USA), Tempus AI (USA), NeoGenomics (USA), Natera (USA), OncoDNA (Belgium), Agendia (Netherlands), Eurofins Clinical Diagnostics (Luxembourg), Unilabs Genetics (Switzerland), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Genomic Cancer Testing market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Genomic Cancer Testing Market, By Region:
1. How big is the global Genomic Cancer Testing market?
2. What is the demand of the global Genomic Cancer Testing market?
3. What is the year over year growth of the global Genomic Cancer Testing market?
4. What is the total value of the global Genomic Cancer Testing market?
5. Who are the Major Players in the global Genomic Cancer Testing market?
6. What are the growth factors driving the market demand?
Genomic Cancer Testing refers to a class of molecular diagnostic technologies and services that analyze DNA, RNA and other molecular-level genetic information in a patient's tumor tissue or body fluids (such as circulating tumor DNA, ctDNA in blood) to identify gene mutations, copy number variations, gene fusions, abnormal expression or epigenetic changes related to the occurrence, development, subtype, treatment response and recurrence of cancer.
Gross Profit Margin Levels
Genomic cancer testing is an industry with high technological barriers, high data interpretation value, but also highly dependent on laboratory automation, sample size, and payment coverage. Overall, the industry's gross profit margin is typically significantly higher than that of routine testing projects. Based on comparable listed companies and industry experience, the gross profit margin for tumor gene testing business at comprehensive laboratory companies is commonly in the 50%-60% range, while leading pure molecular diagnostics/liquid biopsy/high-end CGP companies can typically reach 60%-75%. Among these, product lines with high automation, strong data reuse capabilities, high report added value, and good medical/commercial insurance coverage usually have even higher gross profit margins. Conversely, if a company primarily focuses on customized projects, low-throughput orders, complex manual interpretation, or regional sample delivery services, the gross profit margin will be diluted by channel costs, labor costs, and logistics costs. Therefore, the core of this industry is not 'how much money is made per sample tested,' but rather the quality of profitability is determined by platform-based testing capabilities, database capabilities, clinical evidence capabilities, and payment capabilities. The average gross profit margin level in this industry can generally be understood as higher than traditional pathology testing, lower than pure software SaaS, but significantly higher than most routine outsourced testing projects.
Industry Drivers
The growth of the genomic cancer testing industry is primarily driven by the continued rise in the cancer burden. WHO/IARC data shows that nearly 20 million new cancer cases were diagnosed globally in 2022, and this number is projected to reach 35 million by 2050. This directly increases the long-term demand for early screening, subtyping, targeted therapy selection, efficacy evaluation, and recurrence monitoring. Secondly, the increasing penetration rate of precision medicine is the most crucial catalyst for the industry. The NCI has explicitly incorporated biomarker testing into its treatment decision-making process, and the increasing number of FDA-approved companion diagnostics means that more and more anti-tumor drugs will rely on molecular testing for patient screening. Thirdly, improvements in the payment and regulatory environment are transforming tumor gene testing from an 'optional item' into 'part of the standard process'?the extension of CMS's NGS coverage policy and the clear payment pricing for high-value CGP projects are strengthening the industry's business loop. Meanwhile, liquid biopsy, methylation detection, MRD, AI interpretation, and multi-omics joint analysis are continuously improving detection sensitivity, lowering sampling thresholds, and extending testing scenarios from single-diagnosis to full-course disease management. Finally, pharmaceutical companies' demand for companion diagnostics, biomarker discovery, patient stratification, and real-world evidence is also driving the industry to upgrade from a single testing business to a composite market encompassing clinical services, drug development, and data asset operation.
This report studies the global Genomic Cancer Testing demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Genomic Cancer Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Genomic Cancer Testing that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Genomic Cancer Testing total market, 2021-2032, (USD Million)
Global Genomic Cancer Testing total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Genomic Cancer Testing total market, key domestic companies, and share, (USD Million)
Global Genomic Cancer Testing revenue by player, revenue and market share 2021-2026, (USD Million)
Global Genomic Cancer Testing total market by Type, CAGR, 2021-2032, (USD Million)
Global Genomic Cancer Testing total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Genomic Cancer Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Guardant Health (USA), Foundation Medicine (USA), Caris Life Sciences (USA), Tempus AI (USA), NeoGenomics (USA), Natera (USA), OncoDNA (Belgium), Agendia (Netherlands), Eurofins Clinical Diagnostics (Luxembourg), Unilabs Genetics (Switzerland), etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Genomic Cancer Testing market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Genomic Cancer Testing Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Next-Generation Sequencing (NGS) Testing Products
- Digital PCR (dPCR) Testing Products
- Others
- Tissue Sample Testing
- Blood Biopsy
- Others
- Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
- Genome Testing Products Specifically For Single Cancer Types
- Others
- Healthcare Institutions
- Biopharmaceuticals and Pharmaceuticals
- Independent Medical Laboratories
- Others
- Guardant Health (USA)
- Foundation Medicine (USA)
- Caris Life Sciences (USA)
- Tempus AI (USA)
- NeoGenomics (USA)
- Natera (USA)
- OncoDNA (Belgium)
- Agendia (Netherlands)
- Eurofins Clinical Diagnostics (Luxembourg)
- Unilabs Genetics (Switzerland)
- Nucleix (Israel)
- Genetron Health (China)
- Macrogen (South Korea)
- Geneseeq (China)
- 3DMed (China)
- BGI Genomics (China)
- Canhelp Genomics (China)
- Lucence (Singapore)
- MiRXES (Singapore)
- ACT Genomics (Taiwan)
- MedGenome (India)
- Strand Life Sciences (India)
- Sonic Genetics (Australia)
- NeoGenomics (USA)
- Labcorp Oncology (USA)
1. How big is the global Genomic Cancer Testing market?
2. What is the demand of the global Genomic Cancer Testing market?
3. What is the year over year growth of the global Genomic Cancer Testing market?
4. What is the total value of the global Genomic Cancer Testing market?
5. Who are the Major Players in the global Genomic Cancer Testing market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Genomic Cancer Testing Introduction
1.2 World Genomic Cancer Testing Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Genomic Cancer Testing Total Market by Region (by Headquarter Location)
1.3.1 World Genomic Cancer Testing Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.3 China Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.4 Europe Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.5 Japan Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.6 South Korea Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.7 ASEAN Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.8 India Based Company Genomic Cancer Testing Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Genomic Cancer Testing Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Genomic Cancer Testing Consumption Value (2021-2032)
2.2 World Genomic Cancer Testing Consumption Value by Region
2.2.1 World Genomic Cancer Testing Consumption Value by Region (2021-2026)
2.2.2 World Genomic Cancer Testing Consumption Value Forecast by Region (2027-2032)
2.3 United States Genomic Cancer Testing Consumption Value (2021-2032)
2.4 China Genomic Cancer Testing Consumption Value (2021-2032)
2.5 Europe Genomic Cancer Testing Consumption Value (2021-2032)
2.6 Japan Genomic Cancer Testing Consumption Value (2021-2032)
2.7 South Korea Genomic Cancer Testing Consumption Value (2021-2032)
2.8 ASEAN Genomic Cancer Testing Consumption Value (2021-2032)
2.9 India Genomic Cancer Testing Consumption Value (2021-2032)
3 WORLD GENOMIC CANCER TESTING COMPANIES COMPETITIVE ANALYSIS
3.1 World Genomic Cancer Testing Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Genomic Cancer Testing Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Genomic Cancer Testing in 2025
3.2.3 Global Concentration Ratios (CR8) for Genomic Cancer Testing in 2025
3.3 Genomic Cancer Testing Company Evaluation Quadrant
3.4 Genomic Cancer Testing Market: Overall Company Footprint Analysis
3.4.1 Genomic Cancer Testing Market: Region Footprint
3.4.2 Genomic Cancer Testing Market: Company Product Type Footprint
3.4.3 Genomic Cancer Testing Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Genomic Cancer Testing Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Genomic Cancer Testing Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Genomic Cancer Testing Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Genomic Cancer Testing Consumption Value Comparison
4.2.1 United States VS China: Genomic Cancer Testing Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Genomic Cancer Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Genomic Cancer Testing Companies and Market Share, 2021-2026
4.3.1 United States Based Genomic Cancer Testing Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Genomic Cancer Testing Revenue, (2021-2026)
4.4 China Based Companies Genomic Cancer Testing Revenue and Market Share, 2021-2026
4.4.1 China Based Genomic Cancer Testing Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Genomic Cancer Testing Revenue, (2021-2026)
4.5 Rest of World Based Genomic Cancer Testing Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Genomic Cancer Testing Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Genomic Cancer Testing Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Genomic Cancer Testing Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Next-Generation Sequencing (NGS) Testing Products
5.2.2 Digital PCR (dPCR) Testing Products
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Genomic Cancer Testing Market Size by Type (2021-2026)
5.3.2 World Genomic Cancer Testing Market Size by Type (2027-2032)
5.3.3 World Genomic Cancer Testing Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SAMPLE TYPE
6.1 World Genomic Cancer Testing Market Size Overview by Sample Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Sample Type
6.2.1 Tissue Sample Testing
6.2.2 Blood Biopsy
6.2.3 Others
6.3 Market Segment by Sample Type
6.3.1 World Genomic Cancer Testing Market Size by Sample Type (2021-2026)
6.3.2 World Genomic Cancer Testing Market Size by Sample Type (2027-2032)
6.3.3 World Genomic Cancer Testing Market Size Market Share by Sample Type (2027-2032)
7 MARKET ANALYSIS BY CANCER TYPE COVERAGE
7.1 World Genomic Cancer Testing Market Size Overview by Cancer Type Coverage: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Cancer Type Coverage
7.2.1 Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
7.2.2 Genome Testing Products Specifically For Single Cancer Types
7.2.3 Others
7.3 Market Segment by Cancer Type Coverage
7.3.1 World Genomic Cancer Testing Market Size by Cancer Type Coverage (2021-2026)
7.3.2 World Genomic Cancer Testing Market Size by Cancer Type Coverage (2027-2032)
7.3.3 World Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Genomic Cancer Testing Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Healthcare Institutions
8.2.2 Biopharmaceuticals and Pharmaceuticals
8.2.3 Independent Medical Laboratories
8.2.4 Others
8.3 Market Segment by Application
8.3.1 World Genomic Cancer Testing Market Size by Application (2021-2026)
8.3.2 World Genomic Cancer Testing Market Size by Application (2027-2032)
8.3.3 World Genomic Cancer Testing Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Guardant Health (USA)
9.1.1 Guardant Health (USA) Details
9.1.2 Guardant Health (USA) Major Business
9.1.3 Guardant Health (USA) Genomic Cancer Testing Product and Services
9.1.4 Guardant Health (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Guardant Health (USA) Recent Developments/Updates
9.1.6 Guardant Health (USA) Competitive Strengths & Weaknesses
9.2 Foundation Medicine (USA)
9.2.1 Foundation Medicine (USA) Details
9.2.2 Foundation Medicine (USA) Major Business
9.2.3 Foundation Medicine (USA) Genomic Cancer Testing Product and Services
9.2.4 Foundation Medicine (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Foundation Medicine (USA) Recent Developments/Updates
9.2.6 Foundation Medicine (USA) Competitive Strengths & Weaknesses
9.3 Caris Life Sciences (USA)
9.3.1 Caris Life Sciences (USA) Details
9.3.2 Caris Life Sciences (USA) Major Business
9.3.3 Caris Life Sciences (USA) Genomic Cancer Testing Product and Services
9.3.4 Caris Life Sciences (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Caris Life Sciences (USA) Recent Developments/Updates
9.3.6 Caris Life Sciences (USA) Competitive Strengths & Weaknesses
9.4 Tempus AI (USA)
9.4.1 Tempus AI (USA) Details
9.4.2 Tempus AI (USA) Major Business
9.4.3 Tempus AI (USA) Genomic Cancer Testing Product and Services
9.4.4 Tempus AI (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Tempus AI (USA) Recent Developments/Updates
9.4.6 Tempus AI (USA) Competitive Strengths & Weaknesses
9.5 NeoGenomics (USA)
9.5.1 NeoGenomics (USA) Details
9.5.2 NeoGenomics (USA) Major Business
9.5.3 NeoGenomics (USA) Genomic Cancer Testing Product and Services
9.5.4 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 NeoGenomics (USA) Recent Developments/Updates
9.5.6 NeoGenomics (USA) Competitive Strengths & Weaknesses
9.6 Natera (USA)
9.6.1 Natera (USA) Details
9.6.2 Natera (USA) Major Business
9.6.3 Natera (USA) Genomic Cancer Testing Product and Services
9.6.4 Natera (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Natera (USA) Recent Developments/Updates
9.6.6 Natera (USA) Competitive Strengths & Weaknesses
9.7 OncoDNA (Belgium)
9.7.1 OncoDNA (Belgium) Details
9.7.2 OncoDNA (Belgium) Major Business
9.7.3 OncoDNA (Belgium) Genomic Cancer Testing Product and Services
9.7.4 OncoDNA (Belgium) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 OncoDNA (Belgium) Recent Developments/Updates
9.7.6 OncoDNA (Belgium) Competitive Strengths & Weaknesses
9.8 Agendia (Netherlands)
9.8.1 Agendia (Netherlands) Details
9.8.2 Agendia (Netherlands) Major Business
9.8.3 Agendia (Netherlands) Genomic Cancer Testing Product and Services
9.8.4 Agendia (Netherlands) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Agendia (Netherlands) Recent Developments/Updates
9.8.6 Agendia (Netherlands) Competitive Strengths & Weaknesses
9.9 Eurofins Clinical Diagnostics (Luxembourg)
9.9.1 Eurofins Clinical Diagnostics (Luxembourg) Details
9.9.2 Eurofins Clinical Diagnostics (Luxembourg) Major Business
9.9.3 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Product and Services
9.9.4 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Eurofins Clinical Diagnostics (Luxembourg) Recent Developments/Updates
9.9.6 Eurofins Clinical Diagnostics (Luxembourg) Competitive Strengths & Weaknesses
9.10 Unilabs Genetics (Switzerland)
9.10.1 Unilabs Genetics (Switzerland) Details
9.10.2 Unilabs Genetics (Switzerland) Major Business
9.10.3 Unilabs Genetics (Switzerland) Genomic Cancer Testing Product and Services
9.10.4 Unilabs Genetics (Switzerland) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Unilabs Genetics (Switzerland) Recent Developments/Updates
9.10.6 Unilabs Genetics (Switzerland) Competitive Strengths & Weaknesses
9.11 Nucleix (Israel)
9.11.1 Nucleix (Israel) Details
9.11.2 Nucleix (Israel) Major Business
9.11.3 Nucleix (Israel) Genomic Cancer Testing Product and Services
9.11.4 Nucleix (Israel) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Nucleix (Israel) Recent Developments/Updates
9.11.6 Nucleix (Israel) Competitive Strengths & Weaknesses
9.12 Genetron Health (China)
9.12.1 Genetron Health (China) Details
9.12.2 Genetron Health (China) Major Business
9.12.3 Genetron Health (China) Genomic Cancer Testing Product and Services
9.12.4 Genetron Health (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Genetron Health (China) Recent Developments/Updates
9.12.6 Genetron Health (China) Competitive Strengths & Weaknesses
9.13 Macrogen (South Korea)
9.13.1 Macrogen (South Korea) Details
9.13.2 Macrogen (South Korea) Major Business
9.13.3 Macrogen (South Korea) Genomic Cancer Testing Product and Services
9.13.4 Macrogen (South Korea) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Macrogen (South Korea) Recent Developments/Updates
9.13.6 Macrogen (South Korea) Competitive Strengths & Weaknesses
9.14 Geneseeq (China)
9.14.1 Geneseeq (China) Details
9.14.2 Geneseeq (China) Major Business
9.14.3 Geneseeq (China) Genomic Cancer Testing Product and Services
9.14.4 Geneseeq (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Geneseeq (China) Recent Developments/Updates
9.14.6 Geneseeq (China) Competitive Strengths & Weaknesses
9.15 3DMed (China)
9.15.1 3DMed (China) Details
9.15.2 3DMed (China) Major Business
9.15.3 3DMed (China) Genomic Cancer Testing Product and Services
9.15.4 3DMed (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 3DMed (China) Recent Developments/Updates
9.15.6 3DMed (China) Competitive Strengths & Weaknesses
9.16 BGI Genomics (China)
9.16.1 BGI Genomics (China) Details
9.16.2 BGI Genomics (China) Major Business
9.16.3 BGI Genomics (China) Genomic Cancer Testing Product and Services
9.16.4 BGI Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 BGI Genomics (China) Recent Developments/Updates
9.16.6 BGI Genomics (China) Competitive Strengths & Weaknesses
9.17 Canhelp Genomics (China)
9.17.1 Canhelp Genomics (China) Details
9.17.2 Canhelp Genomics (China) Major Business
9.17.3 Canhelp Genomics (China) Genomic Cancer Testing Product and Services
9.17.4 Canhelp Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Canhelp Genomics (China) Recent Developments/Updates
9.17.6 Canhelp Genomics (China) Competitive Strengths & Weaknesses
9.18 Lucence (Singapore)
9.18.1 Lucence (Singapore) Details
9.18.2 Lucence (Singapore) Major Business
9.18.3 Lucence (Singapore) Genomic Cancer Testing Product and Services
9.18.4 Lucence (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Lucence (Singapore) Recent Developments/Updates
9.18.6 Lucence (Singapore) Competitive Strengths & Weaknesses
9.19 MiRXES (Singapore)
9.19.1 MiRXES (Singapore) Details
9.19.2 MiRXES (Singapore) Major Business
9.19.3 MiRXES (Singapore) Genomic Cancer Testing Product and Services
9.19.4 MiRXES (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 MiRXES (Singapore) Recent Developments/Updates
9.19.6 MiRXES (Singapore) Competitive Strengths & Weaknesses
9.20 ACT Genomics (Taiwan)
9.20.1 ACT Genomics (Taiwan) Details
9.20.2 ACT Genomics (Taiwan) Major Business
9.20.3 ACT Genomics (Taiwan) Genomic Cancer Testing Product and Services
9.20.4 ACT Genomics (Taiwan) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 ACT Genomics (Taiwan) Recent Developments/Updates
9.20.6 ACT Genomics (Taiwan) Competitive Strengths & Weaknesses
9.21 MedGenome (India)
9.21.1 MedGenome (India) Details
9.21.2 MedGenome (India) Major Business
9.21.3 MedGenome (India) Genomic Cancer Testing Product and Services
9.21.4 MedGenome (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 MedGenome (India) Recent Developments/Updates
9.21.6 MedGenome (India) Competitive Strengths & Weaknesses
9.22 Strand Life Sciences (India)
9.22.1 Strand Life Sciences (India) Details
9.22.2 Strand Life Sciences (India) Major Business
9.22.3 Strand Life Sciences (India) Genomic Cancer Testing Product and Services
9.22.4 Strand Life Sciences (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Strand Life Sciences (India) Recent Developments/Updates
9.22.6 Strand Life Sciences (India) Competitive Strengths & Weaknesses
9.23 Sonic Genetics (Australia)
9.23.1 Sonic Genetics (Australia) Details
9.23.2 Sonic Genetics (Australia) Major Business
9.23.3 Sonic Genetics (Australia) Genomic Cancer Testing Product and Services
9.23.4 Sonic Genetics (Australia) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Sonic Genetics (Australia) Recent Developments/Updates
9.23.6 Sonic Genetics (Australia) Competitive Strengths & Weaknesses
9.24 NeoGenomics (USA)
9.24.1 NeoGenomics (USA) Details
9.24.2 NeoGenomics (USA) Major Business
9.24.3 NeoGenomics (USA) Genomic Cancer Testing Product and Services
9.24.4 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 NeoGenomics (USA) Recent Developments/Updates
9.24.6 NeoGenomics (USA) Competitive Strengths & Weaknesses
9.25 Labcorp Oncology (USA)
9.25.1 Labcorp Oncology (USA) Details
9.25.2 Labcorp Oncology (USA) Major Business
9.25.3 Labcorp Oncology (USA) Genomic Cancer Testing Product and Services
9.25.4 Labcorp Oncology (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Labcorp Oncology (USA) Recent Developments/Updates
9.25.6 Labcorp Oncology (USA) Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Genomic Cancer Testing Industry Chain
10.2 Genomic Cancer Testing Upstream Analysis
10.3 Genomic Cancer Testing Midstream Analysis
10.4 Genomic Cancer Testing Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Genomic Cancer Testing Introduction
1.2 World Genomic Cancer Testing Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Genomic Cancer Testing Total Market by Region (by Headquarter Location)
1.3.1 World Genomic Cancer Testing Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.3 China Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.4 Europe Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.5 Japan Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.6 South Korea Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.7 ASEAN Based Company Genomic Cancer Testing Revenue (2021-2032)
1.3.8 India Based Company Genomic Cancer Testing Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Genomic Cancer Testing Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Genomic Cancer Testing Consumption Value (2021-2032)
2.2 World Genomic Cancer Testing Consumption Value by Region
2.2.1 World Genomic Cancer Testing Consumption Value by Region (2021-2026)
2.2.2 World Genomic Cancer Testing Consumption Value Forecast by Region (2027-2032)
2.3 United States Genomic Cancer Testing Consumption Value (2021-2032)
2.4 China Genomic Cancer Testing Consumption Value (2021-2032)
2.5 Europe Genomic Cancer Testing Consumption Value (2021-2032)
2.6 Japan Genomic Cancer Testing Consumption Value (2021-2032)
2.7 South Korea Genomic Cancer Testing Consumption Value (2021-2032)
2.8 ASEAN Genomic Cancer Testing Consumption Value (2021-2032)
2.9 India Genomic Cancer Testing Consumption Value (2021-2032)
3 WORLD GENOMIC CANCER TESTING COMPANIES COMPETITIVE ANALYSIS
3.1 World Genomic Cancer Testing Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Genomic Cancer Testing Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Genomic Cancer Testing in 2025
3.2.3 Global Concentration Ratios (CR8) for Genomic Cancer Testing in 2025
3.3 Genomic Cancer Testing Company Evaluation Quadrant
3.4 Genomic Cancer Testing Market: Overall Company Footprint Analysis
3.4.1 Genomic Cancer Testing Market: Region Footprint
3.4.2 Genomic Cancer Testing Market: Company Product Type Footprint
3.4.3 Genomic Cancer Testing Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Genomic Cancer Testing Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Genomic Cancer Testing Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Genomic Cancer Testing Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Genomic Cancer Testing Consumption Value Comparison
4.2.1 United States VS China: Genomic Cancer Testing Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Genomic Cancer Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Genomic Cancer Testing Companies and Market Share, 2021-2026
4.3.1 United States Based Genomic Cancer Testing Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Genomic Cancer Testing Revenue, (2021-2026)
4.4 China Based Companies Genomic Cancer Testing Revenue and Market Share, 2021-2026
4.4.1 China Based Genomic Cancer Testing Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Genomic Cancer Testing Revenue, (2021-2026)
4.5 Rest of World Based Genomic Cancer Testing Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Genomic Cancer Testing Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Genomic Cancer Testing Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Genomic Cancer Testing Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Next-Generation Sequencing (NGS) Testing Products
5.2.2 Digital PCR (dPCR) Testing Products
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Genomic Cancer Testing Market Size by Type (2021-2026)
5.3.2 World Genomic Cancer Testing Market Size by Type (2027-2032)
5.3.3 World Genomic Cancer Testing Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SAMPLE TYPE
6.1 World Genomic Cancer Testing Market Size Overview by Sample Type: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Sample Type
6.2.1 Tissue Sample Testing
6.2.2 Blood Biopsy
6.2.3 Others
6.3 Market Segment by Sample Type
6.3.1 World Genomic Cancer Testing Market Size by Sample Type (2021-2026)
6.3.2 World Genomic Cancer Testing Market Size by Sample Type (2027-2032)
6.3.3 World Genomic Cancer Testing Market Size Market Share by Sample Type (2027-2032)
7 MARKET ANALYSIS BY CANCER TYPE COVERAGE
7.1 World Genomic Cancer Testing Market Size Overview by Cancer Type Coverage: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Cancer Type Coverage
7.2.1 Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
7.2.2 Genome Testing Products Specifically For Single Cancer Types
7.2.3 Others
7.3 Market Segment by Cancer Type Coverage
7.3.1 World Genomic Cancer Testing Market Size by Cancer Type Coverage (2021-2026)
7.3.2 World Genomic Cancer Testing Market Size by Cancer Type Coverage (2027-2032)
7.3.3 World Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Genomic Cancer Testing Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Healthcare Institutions
8.2.2 Biopharmaceuticals and Pharmaceuticals
8.2.3 Independent Medical Laboratories
8.2.4 Others
8.3 Market Segment by Application
8.3.1 World Genomic Cancer Testing Market Size by Application (2021-2026)
8.3.2 World Genomic Cancer Testing Market Size by Application (2027-2032)
8.3.3 World Genomic Cancer Testing Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Guardant Health (USA)
9.1.1 Guardant Health (USA) Details
9.1.2 Guardant Health (USA) Major Business
9.1.3 Guardant Health (USA) Genomic Cancer Testing Product and Services
9.1.4 Guardant Health (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Guardant Health (USA) Recent Developments/Updates
9.1.6 Guardant Health (USA) Competitive Strengths & Weaknesses
9.2 Foundation Medicine (USA)
9.2.1 Foundation Medicine (USA) Details
9.2.2 Foundation Medicine (USA) Major Business
9.2.3 Foundation Medicine (USA) Genomic Cancer Testing Product and Services
9.2.4 Foundation Medicine (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Foundation Medicine (USA) Recent Developments/Updates
9.2.6 Foundation Medicine (USA) Competitive Strengths & Weaknesses
9.3 Caris Life Sciences (USA)
9.3.1 Caris Life Sciences (USA) Details
9.3.2 Caris Life Sciences (USA) Major Business
9.3.3 Caris Life Sciences (USA) Genomic Cancer Testing Product and Services
9.3.4 Caris Life Sciences (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Caris Life Sciences (USA) Recent Developments/Updates
9.3.6 Caris Life Sciences (USA) Competitive Strengths & Weaknesses
9.4 Tempus AI (USA)
9.4.1 Tempus AI (USA) Details
9.4.2 Tempus AI (USA) Major Business
9.4.3 Tempus AI (USA) Genomic Cancer Testing Product and Services
9.4.4 Tempus AI (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Tempus AI (USA) Recent Developments/Updates
9.4.6 Tempus AI (USA) Competitive Strengths & Weaknesses
9.5 NeoGenomics (USA)
9.5.1 NeoGenomics (USA) Details
9.5.2 NeoGenomics (USA) Major Business
9.5.3 NeoGenomics (USA) Genomic Cancer Testing Product and Services
9.5.4 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 NeoGenomics (USA) Recent Developments/Updates
9.5.6 NeoGenomics (USA) Competitive Strengths & Weaknesses
9.6 Natera (USA)
9.6.1 Natera (USA) Details
9.6.2 Natera (USA) Major Business
9.6.3 Natera (USA) Genomic Cancer Testing Product and Services
9.6.4 Natera (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Natera (USA) Recent Developments/Updates
9.6.6 Natera (USA) Competitive Strengths & Weaknesses
9.7 OncoDNA (Belgium)
9.7.1 OncoDNA (Belgium) Details
9.7.2 OncoDNA (Belgium) Major Business
9.7.3 OncoDNA (Belgium) Genomic Cancer Testing Product and Services
9.7.4 OncoDNA (Belgium) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 OncoDNA (Belgium) Recent Developments/Updates
9.7.6 OncoDNA (Belgium) Competitive Strengths & Weaknesses
9.8 Agendia (Netherlands)
9.8.1 Agendia (Netherlands) Details
9.8.2 Agendia (Netherlands) Major Business
9.8.3 Agendia (Netherlands) Genomic Cancer Testing Product and Services
9.8.4 Agendia (Netherlands) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Agendia (Netherlands) Recent Developments/Updates
9.8.6 Agendia (Netherlands) Competitive Strengths & Weaknesses
9.9 Eurofins Clinical Diagnostics (Luxembourg)
9.9.1 Eurofins Clinical Diagnostics (Luxembourg) Details
9.9.2 Eurofins Clinical Diagnostics (Luxembourg) Major Business
9.9.3 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Product and Services
9.9.4 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Eurofins Clinical Diagnostics (Luxembourg) Recent Developments/Updates
9.9.6 Eurofins Clinical Diagnostics (Luxembourg) Competitive Strengths & Weaknesses
9.10 Unilabs Genetics (Switzerland)
9.10.1 Unilabs Genetics (Switzerland) Details
9.10.2 Unilabs Genetics (Switzerland) Major Business
9.10.3 Unilabs Genetics (Switzerland) Genomic Cancer Testing Product and Services
9.10.4 Unilabs Genetics (Switzerland) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Unilabs Genetics (Switzerland) Recent Developments/Updates
9.10.6 Unilabs Genetics (Switzerland) Competitive Strengths & Weaknesses
9.11 Nucleix (Israel)
9.11.1 Nucleix (Israel) Details
9.11.2 Nucleix (Israel) Major Business
9.11.3 Nucleix (Israel) Genomic Cancer Testing Product and Services
9.11.4 Nucleix (Israel) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Nucleix (Israel) Recent Developments/Updates
9.11.6 Nucleix (Israel) Competitive Strengths & Weaknesses
9.12 Genetron Health (China)
9.12.1 Genetron Health (China) Details
9.12.2 Genetron Health (China) Major Business
9.12.3 Genetron Health (China) Genomic Cancer Testing Product and Services
9.12.4 Genetron Health (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Genetron Health (China) Recent Developments/Updates
9.12.6 Genetron Health (China) Competitive Strengths & Weaknesses
9.13 Macrogen (South Korea)
9.13.1 Macrogen (South Korea) Details
9.13.2 Macrogen (South Korea) Major Business
9.13.3 Macrogen (South Korea) Genomic Cancer Testing Product and Services
9.13.4 Macrogen (South Korea) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Macrogen (South Korea) Recent Developments/Updates
9.13.6 Macrogen (South Korea) Competitive Strengths & Weaknesses
9.14 Geneseeq (China)
9.14.1 Geneseeq (China) Details
9.14.2 Geneseeq (China) Major Business
9.14.3 Geneseeq (China) Genomic Cancer Testing Product and Services
9.14.4 Geneseeq (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Geneseeq (China) Recent Developments/Updates
9.14.6 Geneseeq (China) Competitive Strengths & Weaknesses
9.15 3DMed (China)
9.15.1 3DMed (China) Details
9.15.2 3DMed (China) Major Business
9.15.3 3DMed (China) Genomic Cancer Testing Product and Services
9.15.4 3DMed (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 3DMed (China) Recent Developments/Updates
9.15.6 3DMed (China) Competitive Strengths & Weaknesses
9.16 BGI Genomics (China)
9.16.1 BGI Genomics (China) Details
9.16.2 BGI Genomics (China) Major Business
9.16.3 BGI Genomics (China) Genomic Cancer Testing Product and Services
9.16.4 BGI Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 BGI Genomics (China) Recent Developments/Updates
9.16.6 BGI Genomics (China) Competitive Strengths & Weaknesses
9.17 Canhelp Genomics (China)
9.17.1 Canhelp Genomics (China) Details
9.17.2 Canhelp Genomics (China) Major Business
9.17.3 Canhelp Genomics (China) Genomic Cancer Testing Product and Services
9.17.4 Canhelp Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Canhelp Genomics (China) Recent Developments/Updates
9.17.6 Canhelp Genomics (China) Competitive Strengths & Weaknesses
9.18 Lucence (Singapore)
9.18.1 Lucence (Singapore) Details
9.18.2 Lucence (Singapore) Major Business
9.18.3 Lucence (Singapore) Genomic Cancer Testing Product and Services
9.18.4 Lucence (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Lucence (Singapore) Recent Developments/Updates
9.18.6 Lucence (Singapore) Competitive Strengths & Weaknesses
9.19 MiRXES (Singapore)
9.19.1 MiRXES (Singapore) Details
9.19.2 MiRXES (Singapore) Major Business
9.19.3 MiRXES (Singapore) Genomic Cancer Testing Product and Services
9.19.4 MiRXES (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 MiRXES (Singapore) Recent Developments/Updates
9.19.6 MiRXES (Singapore) Competitive Strengths & Weaknesses
9.20 ACT Genomics (Taiwan)
9.20.1 ACT Genomics (Taiwan) Details
9.20.2 ACT Genomics (Taiwan) Major Business
9.20.3 ACT Genomics (Taiwan) Genomic Cancer Testing Product and Services
9.20.4 ACT Genomics (Taiwan) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 ACT Genomics (Taiwan) Recent Developments/Updates
9.20.6 ACT Genomics (Taiwan) Competitive Strengths & Weaknesses
9.21 MedGenome (India)
9.21.1 MedGenome (India) Details
9.21.2 MedGenome (India) Major Business
9.21.3 MedGenome (India) Genomic Cancer Testing Product and Services
9.21.4 MedGenome (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 MedGenome (India) Recent Developments/Updates
9.21.6 MedGenome (India) Competitive Strengths & Weaknesses
9.22 Strand Life Sciences (India)
9.22.1 Strand Life Sciences (India) Details
9.22.2 Strand Life Sciences (India) Major Business
9.22.3 Strand Life Sciences (India) Genomic Cancer Testing Product and Services
9.22.4 Strand Life Sciences (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Strand Life Sciences (India) Recent Developments/Updates
9.22.6 Strand Life Sciences (India) Competitive Strengths & Weaknesses
9.23 Sonic Genetics (Australia)
9.23.1 Sonic Genetics (Australia) Details
9.23.2 Sonic Genetics (Australia) Major Business
9.23.3 Sonic Genetics (Australia) Genomic Cancer Testing Product and Services
9.23.4 Sonic Genetics (Australia) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Sonic Genetics (Australia) Recent Developments/Updates
9.23.6 Sonic Genetics (Australia) Competitive Strengths & Weaknesses
9.24 NeoGenomics (USA)
9.24.1 NeoGenomics (USA) Details
9.24.2 NeoGenomics (USA) Major Business
9.24.3 NeoGenomics (USA) Genomic Cancer Testing Product and Services
9.24.4 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 NeoGenomics (USA) Recent Developments/Updates
9.24.6 NeoGenomics (USA) Competitive Strengths & Weaknesses
9.25 Labcorp Oncology (USA)
9.25.1 Labcorp Oncology (USA) Details
9.25.2 Labcorp Oncology (USA) Major Business
9.25.3 Labcorp Oncology (USA) Genomic Cancer Testing Product and Services
9.25.4 Labcorp Oncology (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Labcorp Oncology (USA) Recent Developments/Updates
9.25.6 Labcorp Oncology (USA) Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Genomic Cancer Testing Industry Chain
10.2 Genomic Cancer Testing Upstream Analysis
10.3 Genomic Cancer Testing Midstream Analysis
10.4 Genomic Cancer Testing Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Genomic Cancer Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Genomic Cancer Testing Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Genomic Cancer Testing Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Genomic Cancer Testing Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Genomic Cancer Testing Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Genomic Cancer Testing Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Genomic Cancer Testing Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Genomic Cancer Testing Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Genomic Cancer Testing Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Genomic Cancer Testing Players in 2025
Table 12. World Genomic Cancer Testing Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Genomic Cancer Testing Company Evaluation Quadrant
Table 14. Head Office of Key Genomic Cancer Testing Players
Table 15. Genomic Cancer Testing Market: Company Product Type Footprint
Table 16. Genomic Cancer Testing Market: Company Product Application Footprint
Table 17. Genomic Cancer Testing Mergers & Acquisitions Activity
Table 18. United States VS China Genomic Cancer Testing Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Genomic Cancer Testing Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Genomic Cancer Testing Companies, Headquarters (States, Country)
Table 21. United States Based Companies Genomic Cancer Testing Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Genomic Cancer Testing Revenue Market Share (2021-2026)
Table 23. China Based Genomic Cancer Testing Companies, Headquarters (Province, Country)
Table 24. China Based Companies Genomic Cancer Testing Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Genomic Cancer Testing Revenue Market Share (2021-2026)
Table 26. Rest of World Based Genomic Cancer Testing Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Genomic Cancer Testing Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Genomic Cancer Testing Revenue Market Share (2021-2026)
Table 29. World Genomic Cancer Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Genomic Cancer Testing Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Genomic Cancer Testing Market Size by Type (2027-2032) & (USD Million)
Table 32. World Genomic Cancer Testing Market Size by Sample Type, (USD Million), 2021 & 2025 & 2032
Table 33. World Genomic Cancer Testing Market Size Value by Sample Type (2021-2026) & (USD Million)
Table 34. World Genomic Cancer Testing Market Size by Sample Type (2027-2032) & (USD Million)
Table 35. World Genomic Cancer Testing Market Size by Cancer Type Coverage, (USD Million), 2021 & 2025 & 2032
Table 36. World Genomic Cancer Testing Market Size Value by Cancer Type Coverage (2021-2026) & (USD Million)
Table 37. World Genomic Cancer Testing Market Size by Cancer Type Coverage (2027-2032) & (USD Million)
Table 38. World Genomic Cancer Testing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Genomic Cancer Testing Market Size by Application (2021-2026) & (USD Million)
Table 40. World Genomic Cancer Testing Market Size by Application (2027-2032) & (USD Million)
Table 41. Guardant Health (USA) Basic Information, Manufacturing Base and Competitors
Table 42. Guardant Health (USA) Major Business
Table 43. Guardant Health (USA) Genomic Cancer Testing Product and Services
Table 44. Guardant Health (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Guardant Health (USA) Recent Developments/Updates
Table 46. Guardant Health (USA) Competitive Strengths & Weaknesses
Table 47. Foundation Medicine (USA) Basic Information, Manufacturing Base and Competitors
Table 48. Foundation Medicine (USA) Major Business
Table 49. Foundation Medicine (USA) Genomic Cancer Testing Product and Services
Table 50. Foundation Medicine (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Foundation Medicine (USA) Recent Developments/Updates
Table 52. Foundation Medicine (USA) Competitive Strengths & Weaknesses
Table 53. Caris Life Sciences (USA) Basic Information, Manufacturing Base and Competitors
Table 54. Caris Life Sciences (USA) Major Business
Table 55. Caris Life Sciences (USA) Genomic Cancer Testing Product and Services
Table 56. Caris Life Sciences (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Caris Life Sciences (USA) Recent Developments/Updates
Table 58. Caris Life Sciences (USA) Competitive Strengths & Weaknesses
Table 59. Tempus AI (USA) Basic Information, Manufacturing Base and Competitors
Table 60. Tempus AI (USA) Major Business
Table 61. Tempus AI (USA) Genomic Cancer Testing Product and Services
Table 62. Tempus AI (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Tempus AI (USA) Recent Developments/Updates
Table 64. Tempus AI (USA) Competitive Strengths & Weaknesses
Table 65. NeoGenomics (USA) Basic Information, Manufacturing Base and Competitors
Table 66. NeoGenomics (USA) Major Business
Table 67. NeoGenomics (USA) Genomic Cancer Testing Product and Services
Table 68. NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. NeoGenomics (USA) Recent Developments/Updates
Table 70. NeoGenomics (USA) Competitive Strengths & Weaknesses
Table 71. Natera (USA) Basic Information, Manufacturing Base and Competitors
Table 72. Natera (USA) Major Business
Table 73. Natera (USA) Genomic Cancer Testing Product and Services
Table 74. Natera (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Natera (USA) Recent Developments/Updates
Table 76. Natera (USA) Competitive Strengths & Weaknesses
Table 77. OncoDNA (Belgium) Basic Information, Manufacturing Base and Competitors
Table 78. OncoDNA (Belgium) Major Business
Table 79. OncoDNA (Belgium) Genomic Cancer Testing Product and Services
Table 80. OncoDNA (Belgium) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. OncoDNA (Belgium) Recent Developments/Updates
Table 82. OncoDNA (Belgium) Competitive Strengths & Weaknesses
Table 83. Agendia (Netherlands) Basic Information, Manufacturing Base and Competitors
Table 84. Agendia (Netherlands) Major Business
Table 85. Agendia (Netherlands) Genomic Cancer Testing Product and Services
Table 86. Agendia (Netherlands) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Agendia (Netherlands) Recent Developments/Updates
Table 88. Agendia (Netherlands) Competitive Strengths & Weaknesses
Table 89. Eurofins Clinical Diagnostics (Luxembourg) Basic Information, Manufacturing Base and Competitors
Table 90. Eurofins Clinical Diagnostics (Luxembourg) Major Business
Table 91. Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Product and Services
Table 92. Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Eurofins Clinical Diagnostics (Luxembourg) Recent Developments/Updates
Table 94. Eurofins Clinical Diagnostics (Luxembourg) Competitive Strengths & Weaknesses
Table 95. Unilabs Genetics (Switzerland) Basic Information, Manufacturing Base and Competitors
Table 96. Unilabs Genetics (Switzerland) Major Business
Table 97. Unilabs Genetics (Switzerland) Genomic Cancer Testing Product and Services
Table 98. Unilabs Genetics (Switzerland) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Unilabs Genetics (Switzerland) Recent Developments/Updates
Table 100. Unilabs Genetics (Switzerland) Competitive Strengths & Weaknesses
Table 101. Nucleix (Israel) Basic Information, Manufacturing Base and Competitors
Table 102. Nucleix (Israel) Major Business
Table 103. Nucleix (Israel) Genomic Cancer Testing Product and Services
Table 104. Nucleix (Israel) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Nucleix (Israel) Recent Developments/Updates
Table 106. Nucleix (Israel) Competitive Strengths & Weaknesses
Table 107. Genetron Health (China) Basic Information, Manufacturing Base and Competitors
Table 108. Genetron Health (China) Major Business
Table 109. Genetron Health (China) Genomic Cancer Testing Product and Services
Table 110. Genetron Health (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Genetron Health (China) Recent Developments/Updates
Table 112. Genetron Health (China) Competitive Strengths & Weaknesses
Table 113. Macrogen (South Korea) Basic Information, Manufacturing Base and Competitors
Table 114. Macrogen (South Korea) Major Business
Table 115. Macrogen (South Korea) Genomic Cancer Testing Product and Services
Table 116. Macrogen (South Korea) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Macrogen (South Korea) Recent Developments/Updates
Table 118. Macrogen (South Korea) Competitive Strengths & Weaknesses
Table 119. Geneseeq (China) Basic Information, Manufacturing Base and Competitors
Table 120. Geneseeq (China) Major Business
Table 121. Geneseeq (China) Genomic Cancer Testing Product and Services
Table 122. Geneseeq (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Geneseeq (China) Recent Developments/Updates
Table 124. Geneseeq (China) Competitive Strengths & Weaknesses
Table 125. 3DMed (China) Basic Information, Manufacturing Base and Competitors
Table 126. 3DMed (China) Major Business
Table 127. 3DMed (China) Genomic Cancer Testing Product and Services
Table 128. 3DMed (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. 3DMed (China) Recent Developments/Updates
Table 130. 3DMed (China) Competitive Strengths & Weaknesses
Table 131. BGI Genomics (China) Basic Information, Manufacturing Base and Competitors
Table 132. BGI Genomics (China) Major Business
Table 133. BGI Genomics (China) Genomic Cancer Testing Product and Services
Table 134. BGI Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. BGI Genomics (China) Recent Developments/Updates
Table 136. BGI Genomics (China) Competitive Strengths & Weaknesses
Table 137. Canhelp Genomics (China) Basic Information, Manufacturing Base and Competitors
Table 138. Canhelp Genomics (China) Major Business
Table 139. Canhelp Genomics (China) Genomic Cancer Testing Product and Services
Table 140. Canhelp Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Canhelp Genomics (China) Recent Developments/Updates
Table 142. Canhelp Genomics (China) Competitive Strengths & Weaknesses
Table 143. Lucence (Singapore) Basic Information, Manufacturing Base and Competitors
Table 144. Lucence (Singapore) Major Business
Table 145. Lucence (Singapore) Genomic Cancer Testing Product and Services
Table 146. Lucence (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Lucence (Singapore) Recent Developments/Updates
Table 148. Lucence (Singapore) Competitive Strengths & Weaknesses
Table 149. MiRXES (Singapore) Basic Information, Manufacturing Base and Competitors
Table 150. MiRXES (Singapore) Major Business
Table 151. MiRXES (Singapore) Genomic Cancer Testing Product and Services
Table 152. MiRXES (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. MiRXES (Singapore) Recent Developments/Updates
Table 154. MiRXES (Singapore) Competitive Strengths & Weaknesses
Table 155. ACT Genomics (Taiwan) Basic Information, Manufacturing Base and Competitors
Table 156. ACT Genomics (Taiwan) Major Business
Table 157. ACT Genomics (Taiwan) Genomic Cancer Testing Product and Services
Table 158. ACT Genomics (Taiwan) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. ACT Genomics (Taiwan) Recent Developments/Updates
Table 160. ACT Genomics (Taiwan) Competitive Strengths & Weaknesses
Table 161. MedGenome (India) Basic Information, Manufacturing Base and Competitors
Table 162. MedGenome (India) Major Business
Table 163. MedGenome (India) Genomic Cancer Testing Product and Services
Table 164. MedGenome (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. MedGenome (India) Recent Developments/Updates
Table 166. MedGenome (India) Competitive Strengths & Weaknesses
Table 167. Strand Life Sciences (India) Basic Information, Manufacturing Base and Competitors
Table 168. Strand Life Sciences (India) Major Business
Table 169. Strand Life Sciences (India) Genomic Cancer Testing Product and Services
Table 170. Strand Life Sciences (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. Strand Life Sciences (India) Recent Developments/Updates
Table 172. Strand Life Sciences (India) Competitive Strengths & Weaknesses
Table 173. Sonic Genetics (Australia) Basic Information, Manufacturing Base and Competitors
Table 174. Sonic Genetics (Australia) Major Business
Table 175. Sonic Genetics (Australia) Genomic Cancer Testing Product and Services
Table 176. Sonic Genetics (Australia) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Sonic Genetics (Australia) Recent Developments/Updates
Table 178. Sonic Genetics (Australia) Competitive Strengths & Weaknesses
Table 179. NeoGenomics (USA) Basic Information, Manufacturing Base and Competitors
Table 180. NeoGenomics (USA) Major Business
Table 181. NeoGenomics (USA) Genomic Cancer Testing Product and Services
Table 182. NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. NeoGenomics (USA) Recent Developments/Updates
Table 184. NeoGenomics (USA) Competitive Strengths & Weaknesses
Table 185. Labcorp Oncology (USA) Basic Information, Manufacturing Base and Competitors
Table 186. Labcorp Oncology (USA) Major Business
Table 187. Labcorp Oncology (USA) Genomic Cancer Testing Product and Services
Table 188. Labcorp Oncology (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Labcorp Oncology (USA) Recent Developments/Updates
Table 190. Labcorp Oncology (USA) Competitive Strengths & Weaknesses
Table 191. Global Key Players of Genomic Cancer Testing Upstream (Raw Materials)
Table 192. Global Genomic Cancer Testing Typical Customers
Table 1. World Genomic Cancer Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Genomic Cancer Testing Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Genomic Cancer Testing Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Genomic Cancer Testing Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Genomic Cancer Testing Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Genomic Cancer Testing Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Genomic Cancer Testing Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Genomic Cancer Testing Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Genomic Cancer Testing Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Genomic Cancer Testing Players in 2025
Table 12. World Genomic Cancer Testing Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Genomic Cancer Testing Company Evaluation Quadrant
Table 14. Head Office of Key Genomic Cancer Testing Players
Table 15. Genomic Cancer Testing Market: Company Product Type Footprint
Table 16. Genomic Cancer Testing Market: Company Product Application Footprint
Table 17. Genomic Cancer Testing Mergers & Acquisitions Activity
Table 18. United States VS China Genomic Cancer Testing Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Genomic Cancer Testing Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Genomic Cancer Testing Companies, Headquarters (States, Country)
Table 21. United States Based Companies Genomic Cancer Testing Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Genomic Cancer Testing Revenue Market Share (2021-2026)
Table 23. China Based Genomic Cancer Testing Companies, Headquarters (Province, Country)
Table 24. China Based Companies Genomic Cancer Testing Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Genomic Cancer Testing Revenue Market Share (2021-2026)
Table 26. Rest of World Based Genomic Cancer Testing Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Genomic Cancer Testing Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Genomic Cancer Testing Revenue Market Share (2021-2026)
Table 29. World Genomic Cancer Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Genomic Cancer Testing Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Genomic Cancer Testing Market Size by Type (2027-2032) & (USD Million)
Table 32. World Genomic Cancer Testing Market Size by Sample Type, (USD Million), 2021 & 2025 & 2032
Table 33. World Genomic Cancer Testing Market Size Value by Sample Type (2021-2026) & (USD Million)
Table 34. World Genomic Cancer Testing Market Size by Sample Type (2027-2032) & (USD Million)
Table 35. World Genomic Cancer Testing Market Size by Cancer Type Coverage, (USD Million), 2021 & 2025 & 2032
Table 36. World Genomic Cancer Testing Market Size Value by Cancer Type Coverage (2021-2026) & (USD Million)
Table 37. World Genomic Cancer Testing Market Size by Cancer Type Coverage (2027-2032) & (USD Million)
Table 38. World Genomic Cancer Testing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Genomic Cancer Testing Market Size by Application (2021-2026) & (USD Million)
Table 40. World Genomic Cancer Testing Market Size by Application (2027-2032) & (USD Million)
Table 41. Guardant Health (USA) Basic Information, Manufacturing Base and Competitors
Table 42. Guardant Health (USA) Major Business
Table 43. Guardant Health (USA) Genomic Cancer Testing Product and Services
Table 44. Guardant Health (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Guardant Health (USA) Recent Developments/Updates
Table 46. Guardant Health (USA) Competitive Strengths & Weaknesses
Table 47. Foundation Medicine (USA) Basic Information, Manufacturing Base and Competitors
Table 48. Foundation Medicine (USA) Major Business
Table 49. Foundation Medicine (USA) Genomic Cancer Testing Product and Services
Table 50. Foundation Medicine (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Foundation Medicine (USA) Recent Developments/Updates
Table 52. Foundation Medicine (USA) Competitive Strengths & Weaknesses
Table 53. Caris Life Sciences (USA) Basic Information, Manufacturing Base and Competitors
Table 54. Caris Life Sciences (USA) Major Business
Table 55. Caris Life Sciences (USA) Genomic Cancer Testing Product and Services
Table 56. Caris Life Sciences (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Caris Life Sciences (USA) Recent Developments/Updates
Table 58. Caris Life Sciences (USA) Competitive Strengths & Weaknesses
Table 59. Tempus AI (USA) Basic Information, Manufacturing Base and Competitors
Table 60. Tempus AI (USA) Major Business
Table 61. Tempus AI (USA) Genomic Cancer Testing Product and Services
Table 62. Tempus AI (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Tempus AI (USA) Recent Developments/Updates
Table 64. Tempus AI (USA) Competitive Strengths & Weaknesses
Table 65. NeoGenomics (USA) Basic Information, Manufacturing Base and Competitors
Table 66. NeoGenomics (USA) Major Business
Table 67. NeoGenomics (USA) Genomic Cancer Testing Product and Services
Table 68. NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. NeoGenomics (USA) Recent Developments/Updates
Table 70. NeoGenomics (USA) Competitive Strengths & Weaknesses
Table 71. Natera (USA) Basic Information, Manufacturing Base and Competitors
Table 72. Natera (USA) Major Business
Table 73. Natera (USA) Genomic Cancer Testing Product and Services
Table 74. Natera (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Natera (USA) Recent Developments/Updates
Table 76. Natera (USA) Competitive Strengths & Weaknesses
Table 77. OncoDNA (Belgium) Basic Information, Manufacturing Base and Competitors
Table 78. OncoDNA (Belgium) Major Business
Table 79. OncoDNA (Belgium) Genomic Cancer Testing Product and Services
Table 80. OncoDNA (Belgium) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. OncoDNA (Belgium) Recent Developments/Updates
Table 82. OncoDNA (Belgium) Competitive Strengths & Weaknesses
Table 83. Agendia (Netherlands) Basic Information, Manufacturing Base and Competitors
Table 84. Agendia (Netherlands) Major Business
Table 85. Agendia (Netherlands) Genomic Cancer Testing Product and Services
Table 86. Agendia (Netherlands) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Agendia (Netherlands) Recent Developments/Updates
Table 88. Agendia (Netherlands) Competitive Strengths & Weaknesses
Table 89. Eurofins Clinical Diagnostics (Luxembourg) Basic Information, Manufacturing Base and Competitors
Table 90. Eurofins Clinical Diagnostics (Luxembourg) Major Business
Table 91. Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Product and Services
Table 92. Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Eurofins Clinical Diagnostics (Luxembourg) Recent Developments/Updates
Table 94. Eurofins Clinical Diagnostics (Luxembourg) Competitive Strengths & Weaknesses
Table 95. Unilabs Genetics (Switzerland) Basic Information, Manufacturing Base and Competitors
Table 96. Unilabs Genetics (Switzerland) Major Business
Table 97. Unilabs Genetics (Switzerland) Genomic Cancer Testing Product and Services
Table 98. Unilabs Genetics (Switzerland) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Unilabs Genetics (Switzerland) Recent Developments/Updates
Table 100. Unilabs Genetics (Switzerland) Competitive Strengths & Weaknesses
Table 101. Nucleix (Israel) Basic Information, Manufacturing Base and Competitors
Table 102. Nucleix (Israel) Major Business
Table 103. Nucleix (Israel) Genomic Cancer Testing Product and Services
Table 104. Nucleix (Israel) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Nucleix (Israel) Recent Developments/Updates
Table 106. Nucleix (Israel) Competitive Strengths & Weaknesses
Table 107. Genetron Health (China) Basic Information, Manufacturing Base and Competitors
Table 108. Genetron Health (China) Major Business
Table 109. Genetron Health (China) Genomic Cancer Testing Product and Services
Table 110. Genetron Health (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Genetron Health (China) Recent Developments/Updates
Table 112. Genetron Health (China) Competitive Strengths & Weaknesses
Table 113. Macrogen (South Korea) Basic Information, Manufacturing Base and Competitors
Table 114. Macrogen (South Korea) Major Business
Table 115. Macrogen (South Korea) Genomic Cancer Testing Product and Services
Table 116. Macrogen (South Korea) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Macrogen (South Korea) Recent Developments/Updates
Table 118. Macrogen (South Korea) Competitive Strengths & Weaknesses
Table 119. Geneseeq (China) Basic Information, Manufacturing Base and Competitors
Table 120. Geneseeq (China) Major Business
Table 121. Geneseeq (China) Genomic Cancer Testing Product and Services
Table 122. Geneseeq (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Geneseeq (China) Recent Developments/Updates
Table 124. Geneseeq (China) Competitive Strengths & Weaknesses
Table 125. 3DMed (China) Basic Information, Manufacturing Base and Competitors
Table 126. 3DMed (China) Major Business
Table 127. 3DMed (China) Genomic Cancer Testing Product and Services
Table 128. 3DMed (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. 3DMed (China) Recent Developments/Updates
Table 130. 3DMed (China) Competitive Strengths & Weaknesses
Table 131. BGI Genomics (China) Basic Information, Manufacturing Base and Competitors
Table 132. BGI Genomics (China) Major Business
Table 133. BGI Genomics (China) Genomic Cancer Testing Product and Services
Table 134. BGI Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. BGI Genomics (China) Recent Developments/Updates
Table 136. BGI Genomics (China) Competitive Strengths & Weaknesses
Table 137. Canhelp Genomics (China) Basic Information, Manufacturing Base and Competitors
Table 138. Canhelp Genomics (China) Major Business
Table 139. Canhelp Genomics (China) Genomic Cancer Testing Product and Services
Table 140. Canhelp Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Canhelp Genomics (China) Recent Developments/Updates
Table 142. Canhelp Genomics (China) Competitive Strengths & Weaknesses
Table 143. Lucence (Singapore) Basic Information, Manufacturing Base and Competitors
Table 144. Lucence (Singapore) Major Business
Table 145. Lucence (Singapore) Genomic Cancer Testing Product and Services
Table 146. Lucence (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Lucence (Singapore) Recent Developments/Updates
Table 148. Lucence (Singapore) Competitive Strengths & Weaknesses
Table 149. MiRXES (Singapore) Basic Information, Manufacturing Base and Competitors
Table 150. MiRXES (Singapore) Major Business
Table 151. MiRXES (Singapore) Genomic Cancer Testing Product and Services
Table 152. MiRXES (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. MiRXES (Singapore) Recent Developments/Updates
Table 154. MiRXES (Singapore) Competitive Strengths & Weaknesses
Table 155. ACT Genomics (Taiwan) Basic Information, Manufacturing Base and Competitors
Table 156. ACT Genomics (Taiwan) Major Business
Table 157. ACT Genomics (Taiwan) Genomic Cancer Testing Product and Services
Table 158. ACT Genomics (Taiwan) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. ACT Genomics (Taiwan) Recent Developments/Updates
Table 160. ACT Genomics (Taiwan) Competitive Strengths & Weaknesses
Table 161. MedGenome (India) Basic Information, Manufacturing Base and Competitors
Table 162. MedGenome (India) Major Business
Table 163. MedGenome (India) Genomic Cancer Testing Product and Services
Table 164. MedGenome (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. MedGenome (India) Recent Developments/Updates
Table 166. MedGenome (India) Competitive Strengths & Weaknesses
Table 167. Strand Life Sciences (India) Basic Information, Manufacturing Base and Competitors
Table 168. Strand Life Sciences (India) Major Business
Table 169. Strand Life Sciences (India) Genomic Cancer Testing Product and Services
Table 170. Strand Life Sciences (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. Strand Life Sciences (India) Recent Developments/Updates
Table 172. Strand Life Sciences (India) Competitive Strengths & Weaknesses
Table 173. Sonic Genetics (Australia) Basic Information, Manufacturing Base and Competitors
Table 174. Sonic Genetics (Australia) Major Business
Table 175. Sonic Genetics (Australia) Genomic Cancer Testing Product and Services
Table 176. Sonic Genetics (Australia) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Sonic Genetics (Australia) Recent Developments/Updates
Table 178. Sonic Genetics (Australia) Competitive Strengths & Weaknesses
Table 179. NeoGenomics (USA) Basic Information, Manufacturing Base and Competitors
Table 180. NeoGenomics (USA) Major Business
Table 181. NeoGenomics (USA) Genomic Cancer Testing Product and Services
Table 182. NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. NeoGenomics (USA) Recent Developments/Updates
Table 184. NeoGenomics (USA) Competitive Strengths & Weaknesses
Table 185. Labcorp Oncology (USA) Basic Information, Manufacturing Base and Competitors
Table 186. Labcorp Oncology (USA) Major Business
Table 187. Labcorp Oncology (USA) Genomic Cancer Testing Product and Services
Table 188. Labcorp Oncology (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Labcorp Oncology (USA) Recent Developments/Updates
Table 190. Labcorp Oncology (USA) Competitive Strengths & Weaknesses
Table 191. Global Key Players of Genomic Cancer Testing Upstream (Raw Materials)
Table 192. Global Genomic Cancer Testing Typical Customers
LIST OF FIGURES
Figure 1. Genomic Cancer Testing Picture
Figure 2. World Genomic Cancer Testing Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Genomic Cancer Testing Total Revenue (2021-2032) & (USD Million)
Figure 4. World Genomic Cancer Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Genomic Cancer Testing Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 13. Genomic Cancer Testing Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 16. World Genomic Cancer Testing Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 18. China Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 23. India Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Genomic Cancer Testing by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Genomic Cancer Testing Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Genomic Cancer Testing Markets in 2025
Figure 27. United States VS China: Genomic Cancer Testing Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Genomic Cancer Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Genomic Cancer Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Genomic Cancer Testing Market Size Market Share by Type in 2025
Figure 31. Next-Generation Sequencing (NGS) Testing Products
Figure 32. Digital PCR (dPCR) Testing Products
Figure 33. Others
Figure 34. World Genomic Cancer Testing Market Size Market Share by Type (2021-2032)
Figure 35. World Genomic Cancer Testing Market Size by Sample Type, (USD Million), 2021 & 2025 & 2032
Figure 36. World Genomic Cancer Testing Market Size Market Share by Sample Type in 2025
Figure 37. Tissue Sample Testing
Figure 38. Blood Biopsy
Figure 39. Others
Figure 40. World Genomic Cancer Testing Market Size Market Share by Sample Type (2021-2032)
Figure 41. World Genomic Cancer Testing Market Size by Cancer Type Coverage, (USD Million), 2021 & 2025 & 2032
Figure 42. World Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage in 2025
Figure 43. Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
Figure 44. Genome Testing Products Specifically For Single Cancer Types
Figure 45. Others
Figure 46. World Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage (2021-2032)
Figure 47. World Genomic Cancer Testing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Genomic Cancer Testing Market Size Market Share by Application in 2025
Figure 49. Healthcare Institutions
Figure 50. Biopharmaceuticals and Pharmaceuticals
Figure 51. Independent Medical Laboratories
Figure 52. Others
Figure 53. World Genomic Cancer Testing Market Size Market Share by Application (2021-2032)
Figure 54. Genomic Cancer Testing Industrial Chain
Figure 55. Methodology
Figure 56. Research Process and Data Source
Figure 1. Genomic Cancer Testing Picture
Figure 2. World Genomic Cancer Testing Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Genomic Cancer Testing Total Revenue (2021-2032) & (USD Million)
Figure 4. World Genomic Cancer Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Genomic Cancer Testing Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Genomic Cancer Testing Revenue (2021-2032) & (USD Million)
Figure 13. Genomic Cancer Testing Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 16. World Genomic Cancer Testing Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 18. China Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 23. India Genomic Cancer Testing Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Genomic Cancer Testing by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Genomic Cancer Testing Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Genomic Cancer Testing Markets in 2025
Figure 27. United States VS China: Genomic Cancer Testing Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Genomic Cancer Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Genomic Cancer Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Genomic Cancer Testing Market Size Market Share by Type in 2025
Figure 31. Next-Generation Sequencing (NGS) Testing Products
Figure 32. Digital PCR (dPCR) Testing Products
Figure 33. Others
Figure 34. World Genomic Cancer Testing Market Size Market Share by Type (2021-2032)
Figure 35. World Genomic Cancer Testing Market Size by Sample Type, (USD Million), 2021 & 2025 & 2032
Figure 36. World Genomic Cancer Testing Market Size Market Share by Sample Type in 2025
Figure 37. Tissue Sample Testing
Figure 38. Blood Biopsy
Figure 39. Others
Figure 40. World Genomic Cancer Testing Market Size Market Share by Sample Type (2021-2032)
Figure 41. World Genomic Cancer Testing Market Size by Cancer Type Coverage, (USD Million), 2021 & 2025 & 2032
Figure 42. World Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage in 2025
Figure 43. Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
Figure 44. Genome Testing Products Specifically For Single Cancer Types
Figure 45. Others
Figure 46. World Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage (2021-2032)
Figure 47. World Genomic Cancer Testing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 48. World Genomic Cancer Testing Market Size Market Share by Application in 2025
Figure 49. Healthcare Institutions
Figure 50. Biopharmaceuticals and Pharmaceuticals
Figure 51. Independent Medical Laboratories
Figure 52. Others
Figure 53. World Genomic Cancer Testing Market Size Market Share by Application (2021-2032)
Figure 54. Genomic Cancer Testing Industrial Chain
Figure 55. Methodology
Figure 56. Research Process and Data Source
